AML-295 AGILE: A Global, Randomized, Double-Blind, Phase 3 Study of Ivosidenib + Azacitidine Versus Placebo + Azacitidine in Patients With Newly Diagnosed Acute Myeloid Leukemia With an IDH1 Mutation

Autores de IIS La Fe

• Pau Montesinos Fernández

  Autor

Participantes ajenos a IIS La Fe

• Dohner H.
• Polo S.V.
• Zarzycka E.
• Wang J.
• Bertani G.
• Heuser M.
• Calado R.T.
• Schuh A.C.
• Yeh S.-P.
• de la Fuente A.
• Cerchione C.
• Daigle S.R.
• Hui J.
• Pandya S.S.
• Gianolio D.A.
• Recher C.
• de Botton S.

Grupos

• Hematología y Hemoterapia

Abstract

Abstract no disponible

Keywords

• azacitidine; isocitrate dehydrogenase 1; ivosidenib; placebo; absolute neutrophil count; acute myeloid leukemia; adverse drug reaction; aged; anemia; Article; blood cell count; blood transfusion; cancer combination chemotherapy; cancer patient; clinical assessment; controlled study; double blind procedure; drug efficacy; drug safety; erythrocyte transfusion; event free survival; febrile neutropenia; human; infection; major clinical study; multiple cycle treatment; outcome assessment; overall survival; phase 3 clinical trial; pneumonia; quality of life; randomized controlled trial; thrombocyte transfusion; thrombocytopenia; treatment response